A Phase 4 interventional study of Lidoderm in Postherpetic Neuralgia, Diabetic Neuropathy and Low Back Pain, sponsored by Endo Pharmaceuticals. Completed at 11 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-01-02.
Sponsored by Endo Pharmaceuticals (part of Keenova Therapeutics plc) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 60 studies in Neuralgia, Postherpetic with a site in United States — 4 open to participants now, 5 under way, none of them phase 3. Neuralgia, Postherpetic · United States.
Among the 60 studies in Neuralgia, Postherpetic with a site in United States, this one is the 24th largest by enrollment of the 56 interventional ones that give a count, is one of 3 that started in 2002, is one of 4 in phase 4, and was the 28th registered.
197 studies on the registry are indexed under Neuralgia, Postherpetic; 29 are open to participants now.
Browse Neuralgia, Postherpetic studies →4 of the 60 studies in Neuralgia, Postherpetic with a site in United States are open now. Recruiting first, the newest first:
Brown University · Sites in United States
Ages 18+ · Healthy volunteers
University of California, San Francisco · Sites in United States
Ages 22–80
University of Minnesota · Sites in United States
Ages 22+
Neurodawn Pharmaceutical Co., Ltd. · Sites in United States
Ages 18–45 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 18 Neuralgia, Postherpetic studies recruiting now, 8 (44%) set no upper age limit and 5 (28%) stop at 75 or younger; none take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
60 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 35 · Phase 3 9 · Phase 4 4
First in 1993; this study’s year is marked. 3 started in 2002.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 107 is above the median of 94 across 163 interventional studies indexed under Neuralgia, Postherpetic.
Median enrollment 93 across the 56 interventional studies, 201 across the 3 observational. Of the 51 that completed or were terminated, 22 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
46 of 60 have an industry lead sponsor. The 10 most frequent:
This study is registered under Endo Pharmaceuticals, one of the names counted as Keenova Therapeutics plc. Under that name alone:
Endo Pharmaceuticals is the lead sponsor of 99 studies on the registry; none are open to participants now.
Of its 16 completed or terminated interventional studies of FDA-regulated products, 14 (88%) have results posted.
Keenova Therapeutics plc has 2 studies filed under Neuralgia, Postherpetic — fewer than ten, so there is no comparison to draw.
1 of the studies in Neuralgia, Postherpetic with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05593237University of California, San FranciscoTranscranial Magnetic Stimulation for Chronic Neuropathic Pain | 2026-12-30 |
Add it to your calendar (.ics) → With an account.
Among the 60 studies in Neuralgia, Postherpetic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Patients with a diagnosis of postherpetic neuralgia (PHN), diabetic neuropathy (DN), or low back pain (LBP) who were currently receiving an analgesic regimen that contained gabapentin participated in a Phase IV clinical trial to assess the effectiveness of Lidoderm® administered once daily (q24h) after 14 day in the treatment of PHN, DN, or LBP in patients who had a partial response to a regimen containing gabapentin.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
(1) Commercially available Lidoderm (lidocaine patch 5%) was provided to patients with up to four patches applied topically once daily (q24h) to the area of maximal peripheral pain.
Drug: Lidoderm
Patients participated in a 2-week treatment period. Commercially available Lidoderm (lidocaine patch 5%) was provided to patients with up to four patches applied topically once daily (q24h) to the area of maximal peripheral pain.
Also known as: Lidocaine patach 5%
Average daily pain intensity (Brief Pain Inventory [BPI] Questions 3, 4, 5, and 6)
Time frame: Visits - V2 (Day 0), V3 (Day 7), V4/EOS (Day 14)
Pain quality using the Neuropathic Pain Scale (NPS)
Time frame: Visits - V2 (Day 0), V3 (Day 7), V4/EOS (Day 14)
Investigator and Patient Global Impression of Change
Time frame: Visits - V2 (Day 0), V3 (Day 7), V4/EOS (Day 14)
Extent of numbness at the site of pain using the Numbness Questionnaire
Time frame: Visits - V2 (Day 0), V3 (Day 7), V4/EOS (Day 14)
Patient Global Assessment of Pain Relief
Time frame: Visits - V2 (Day 0), V3 (Day 7), V4/EOS (Day 14)
Safety assessments included Adverse Events (AE), discontinuation due to AEs, physical and neurological examination results, vital signs, clinical laboratory data, sensory testing, numbness testing, and dermal assessments
Time frame: Visits - V2 (Day 0), V3 (Day 7), V4/EOS (Day 14)
QoL: Pain interference (BPI Question 9)
Time frame: Visits - V2 (Day 0), V3 (Day 7), V4/EOS (Day 14)
QoL: Patient Global Assessment of Patch Satisfaction
Time frame: Visits - V2 (Day 0), V3 (Day 7), V4/EOS (Day 14)
The record gives a start of Jun 2002 and a primary completion of Nov 2002. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lidoderm